It's amazing that you apparently believe you know what the company has or doesn't have in store in terms of funding avenues and/or revenue. The "fact" is that the FDA and the IRB saw more than enough potential in Bucillamine to warrant Phase 3 trials, which are slated to begin this month.
Quote: "But, they need to find a use beyond COVID 19 because the window on that is pretty short, 5 years max,"
Have you any inkling as to how much can occur with Revive in that timeframe, especially if/when Bucillamine and it's other drug treatments prove to be successful?
In addition, from a purely fiscal perspective, many who got in at these levels or lower, will most likely not be here in 5 years as they would have long "cashed out" before that.
That statement was so clearly not well thought out, I couldn't believe you actually stated it publicly.